A familiar molecule. A changing family of medicines.
Semaglutide is a GLP-1 receptor agonist studied for glucose regulation, appetite, weight and selected organ-related outcomes. Understanding it now means distinguishing the molecule from the oral and injectable products, and matching each claim to the trial that tested it.
This guide explains the evidence and current U.S. labeling. Human trial findings apply to specified clinical interventions; they are not efficacy or safety claims for research materials.
What is semaglutide, and is it the same as Ozempic?
Semaglutide is the active molecule. Ozempic, Wegovy and Rybelsus are names associated with finished prescription products. The name of the active ingredient does not tell you the delivery system, approved population or exact clinical use.
A modified GLP-1 peptide with defined structural changes.
How a finished product delivers the molecule into circulation.
A particular population, comparator and measured outcome.
The authorized uses and restrictions for that product.
The molecular design includes an amino-acid substitution that increases resistance to DPP-4 degradation and an attached fatty-acid side chain that promotes albumin binding. Those modifications help prolong exposure compared with native GLP-1. The original discovery paper examined chemistry, receptor activity and preclinical pharmacokinetics; its animal half-life measurements should not be presented as human elimination values. Read the molecular-design study.
The development review explains how these design choices led to injectable and oral formulations. Its historical account is useful for the scientific rationale, while current prescribing information is the appropriate source for today’s product indications. Read the development review.
How does semaglutide work?
Semaglutide activates the GLP-1 receptor, part of a signaling system involved in glucose regulation and appetite. GLP-1 signaling supports glucose-dependent insulin secretion and suppresses glucagon. Pharmacological GLP-1 receptor activation also influences appetite and energy intake, and can affect gastric emptying. The foundational physiology and mechanism reviews separate endogenous hormone biology from the longer exposure produced by medicines. GLP-1 physiology; GLP-1 therapeutic mechanisms.
That is more informative than describing semaglutide as a substance that simply “burns fat.” Weight change is an integrated outcome. A gastric-emptying measurement, a food-intake experiment and a long-term body-weight endpoint are related, but they are not the same experiment.
Eating less and feeling less hungry were measured separately
A 60-week, double-blind study randomized 120 adults to semaglutide or placebo. Researchers measured food consumed at laboratory lunches and also collected subjective appetite ratings.
The semaglutide group had greater reductions in energy intake than placebo at weeks 20, 40 and 60.
Between-group differences in subjective appetite were significant at week 20, but not at weeks 40 or 60.
This was one controlled meal assessment at each visit, not continuous measurement of all daily food intake. Participants also received lifestyle counseling. The study does not prove that a perceived return of hunger means all pharmacological effects have disappeared. Read the primary study.
Oral semaglutide vs injection: what actually differs?
The active molecule can be the same while the delivery problem is different. An oral peptide must contend with degradation and limited absorption. The oral semaglutide formulation studied by Buckley and colleagues combined semaglutide with the absorption enhancer SNAC. Their clinical and dog experiments localized absorption to the stomach near the tablet and investigated protection from degradation and transcellular uptake. Read the absorption study.
This does not show that unformulated semaglutide powder can be swallowed with equivalent results. It also does not establish that two oral formulations, or an oral and injected product, are interchangeable milligram for milligram.
On a narrow screen, scroll or use the keyboard within the comparison table to reach its final column.
| Question | What the evidence addresses | What remains distinct |
|---|---|---|
| Does an oral form work? | PIONEER 1 demonstrated glucose-lowering effects in adults with type 2 diabetes; OASIS 4 studied an oral formulation for weight management. PIONEER 1; OASIS 4. | Clinical exposure depends on the studied formulation and its administration conditions, not just the molecule name. |
| Is one form better for weight? | OASIS 4 and STEP 1 each used placebo controls. A 2026 analysis connected those trials indirectly. Indirect comparison. | That analysis was not a randomized head-to-head trial, and safety outcomes were not formally compared. |
| Are tablets interchangeable? | The current joint Rybelsus/Ozempic tablet label identifies different formulations and explicitly rejects milligram-for-milligram substitution. | Equivalent names, numbers on a package or delivery routes do not establish an individual switching plan. |
The indirect analysis found estimated weight effects that were close under its assumptions. Its methods relied on the comparability of the two trial populations and placebo comparisons; the studies differed in geography and timing. An absence of a statistically significant difference is not, by itself, proof of universal equivalence. The dedicated GLP-1 agonist comparison places these formulation questions in the wider drug-class context.
What is semaglutide’s half-life?
The Ozempic injection label describes circulating semaglutide for about five weeks after the last dose. These are pharmacokinetic descriptions, not a guarantee of precisely when an individual will feel a change in appetite. Read the current injection label.
Half-life describes the decline in drug concentration under specified conditions. It does not tell a laboratory how long a reconstituted sample remains stable, establish an individual washout deadline, or justify a self-directed dosing schedule. Concentration, clinical effect and material stability require different evidence.
Semaglutide weight-loss results: which study are you reading?
14.9% mean loss with semaglutide vs 2.4% with placebo
This trial enrolled adults with obesity, or overweight with a weight-related condition, without diabetes. Both groups received lifestyle support. The primary treatment-policy analysis accounted for treatment discontinuation and rescue interventions. The percentages are averages from that setting, not guaranteed individual results. Read STEP 1.
Oral semaglutide produced 13.6% mean loss vs 2.2% with placebo
The trial tested the specified oral formulation in adults without diabetes. Its primary endpoint was at week 64 within a longer trial. Comparing its headline with STEP 1 does not create a direct oral-versus-injection experiment. Gastrointestinal adverse events occurred more frequently with active treatment. Read OASIS 4.
Population and co-interventions matter. STEP 2 studied adults with type 2 diabetes and found 9.6% mean weight loss with the tested higher semaglutide regimen versus 3.4% with placebo at 68 weeks. STEP 3 paired treatment with intensive behavioral therapy and an initial low-calorie diet, finding 16.0% versus 5.7%. Those are different settings, not competing promises for the same person. STEP 2; STEP 3.
STEP UP later compared higher-dose and standard-dose injected semaglutide with placebo. Its primary treatment-policy analysis found mean reductions of 18.7%, 15.6% and 3.9%, respectively, at 72 weeks. Gastrointestinal events and altered skin sensations were more common with the higher dose. More weight reduction is not evidence that a higher dose is appropriate for every indication or person. Read STEP UP.
What about glucose, cardiovascular, kidney and liver outcomes?
SUSTAIN 1 demonstrated glucose-lowering effects in adults with type 2 diabetes who had not previously received diabetes medicines. Weight was also measured, but this was a diabetes trial rather than a general obesity study. Read SUSTAIN 1.
Cardiovascular outcomes
SELECT enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes. Major cardiovascular events occurred in 6.5% with semaglutide versus 8.0% with placebo. This was a defined high-risk population. SELECT.
Kidney outcomes
FLOW studied 3,533 people with type 2 diabetes and chronic kidney disease. Its hazard ratio of 0.76 concerned a specified composite kidney/CV-death endpoint, not every possible kidney outcome in otherwise healthy people. FLOW.
The earlier SUSTAIN 6 and PIONEER 6 cardiovascular trials used noninferiority designs. PIONEER 6 did not independently prove cardiovascular superiority. The later SOUL trial found fewer major cardiovascular events with oral semaglutide than placebo in adults with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease or both; its confirmatory secondary kidney outcomes were not significantly different. SUSTAIN 6; PIONEER 6; SOUL.
ESSENCE studied metabolic dysfunction-associated steatohepatitis, or MASH, with moderate-to-advanced fibrosis. Its planned interim analysis showed improvements in specified liver-histology endpoints. Those biopsy outcomes should not be rewritten as already-proven reductions in long-term liver failure or death. Read ESSENCE.
What happens when you stop semaglutide?
Keep lifestyle support and the starting point in the result
In the STEP 1 extension, 327 participants were included in the exploratory follow-up analysis. The semaglutide subgroup had previously lost 17.3% on average. During a year after both medication and structured lifestyle support ended, it regained 11.6 percentage points, leaving mean weight 5.6% below the original baseline. This is the source of the “about two-thirds regained” description. Read the extension.
STEP 4 asked a related question while lifestyle support continued. After a 20-week treatment period, 803 participants were randomized to continue semaglutide or switch to placebo. Over the next 48 weeks, the continued group lost a further 7.9%, while the placebo group gained 6.9%, measured from the week-20 weight. Read STEP 4.
The extension was a selected subgroup, not every participant from the original STEP 1 trial. Its 17.3% initial loss therefore should not be substituted for the original trial’s 14.9% headline. Neither study establishes a universal taper, cycling strategy or way to reproduce clinical maintenance with a research reagent.
Current Ozempic, Rybelsus and Wegovy labels
The following product distinctions were checked against U.S. prescribing information on September 9, 2026. They summarize scope; the linked labels contain the full conditions and restrictions.
| Finished product | Specified labeled uses | Important boundary |
|---|---|---|
| Ozempic injection | Adult type 2 diabetes glucose control; specified cardiovascular-risk and type 2 diabetes/chronic-kidney-disease risk indications. | Its label is not a standalone general weight-management indication. Injection label. |
| Rybelsus / Ozempic tablets | Adult type 2 diabetes glucose control and specified cardiovascular-risk reduction. | The joint label describes distinct oral formulations, not milligram-for-milligram substitutes. Tablet label. |
| Wegovy injection | Specified weight-management and cardiovascular uses; adult noncirrhotic MASH with F2–F3 fibrosis under accelerated approval. | The MASH indication remains tied to confirmatory clinical-benefit requirements. Wegovy label. |
| Wegovy tablets | Specified adult weight-management and cardiovascular uses. | The tablet label does not inherit the injection’s pediatric weight-management or MASH indications. Formulation-specific label. |
What are the side effects and important risks?
Digestive symptoms, including nausea, vomiting, diarrhea, constipation and abdominal discomfort, are prominent in the clinical and prescribing-information records. Some participants stopped treatment because of adverse effects. Trial averages do not establish that an individual will tolerate a medicine.
Current labeling includes a boxed warning concerning thyroid C-cell tumors in rodents, with human relevance unknown, and contraindications involving medullary thyroid carcinoma history or MEN2. Other warnings cover pancreatitis, severe gastrointestinal reactions, dehydration-related kidney injury, gallbladder disease, hypersensitivity and aspiration during anesthesia or deep sedation. The complete Ozempic safety information provides the product-specific context.
Diabetic retinopathy complications were more frequent with semaglutide in SUSTAIN 6. That finding deserves explicit attention rather than an assumption that improvement in one endpoint means improvement in every organ outcome. Background insulin or insulin-secretagogue therapy also changes the hypoglycemia discussion. These are clinical assessment questions, not matters a laboratory purity percentage can resolve.
How to read a semaglutide study without losing the context
Start with four items: the exact formulation, the population, the comparator and the endpoint. Then check the time point and analysis. A treatment-policy estimate accounts for events such as discontinuation; an on-treatment or hypothetical adherence estimate answers a different question. Mixing those numbers can create an apparent disagreement where the analyses simply differ.
A direct comparison also has limits. The semaglutide versus tirzepatide evidence guide discusses the tested regimens and outcomes. Semaglutide activates GLP-1 receptors, whereas tirzepatide also engages GIP receptors; receptor count alone is not a clinical ranking system. The GLP-1 and metabolic research hub connects these questions across the wider literature.
What should a laboratory check before sourcing semaglutide research material?
Use the Apex semaglutide research-material page for the current laboratory offering and linked documentation. Check the exact analyte, lot identification, report issuer, methods and applicable handling information. The clinical findings above belong to the specified interventions; they do not establish pharmaceutical equivalence for an Apex reagent.
Chromatographic area purity, identity and calibrated content are different measurements. A single high percentage does not independently demonstrate sterility, endotoxin control, stability under every condition or clinical suitability. The research-grade versus pharmaceutical-grade guide explains the intended-use distinction. Apex research materials are not intended for human or veterinary use.
Frequently Asked Questions About Semaglutide
What is semaglutide?
Semaglutide is a modified peptide that activates the GLP-1 receptor. It is the active ingredient in specified prescription medicines used for type 2 diabetes, weight management and certain cardiovascular, kidney or liver indications. Those uses depend on the finished product, formulation and patient population. A research reagent bearing the same molecule name is not an approved medicine.
How does semaglutide work?
Semaglutide activates GLP-1 receptors involved in glucose regulation and appetite. Its actions include glucose-dependent insulin secretion, suppression of glucagon and reduced energy intake. It also affects gastric emptying. These related actions do not mean that every weight change is caused by food remaining in the stomach or that the molecule simply burns body fat directly.
Is semaglutide the same as Ozempic?
Semaglutide is the active molecule; Ozempic is a brand of finished prescription products. The current United States labeling includes Ozempic injection and a separate joint label for Rybelsus and Ozempic tablets. Brand, formulation and labeled indication must be identified separately. The shared active ingredient does not make every semaglutide material interchangeable.
Does semaglutide come in a pill?
Yes. Approved oral semaglutide products exist, including products covered by the current Rybelsus and Ozempic tablet label and the Wegovy tablet label. These are formulated medicines with specific absorption technology and instructions. Their evidence does not show that swallowing an unformulated research peptide produces the same exposure or effect.
Is oral semaglutide as effective as the injection?
The answer depends on the formulation, outcome and comparison. OASIS 4 tested oral semaglutide against placebo for weight management; STEP 1 tested injected semaglutide against placebo. A 2026 indirect comparison estimated similar weight effects for specified regimens, but it was not a randomized head-to-head trial and did not formally compare safety outcomes. It does not establish universal interchangeability.
What is the half-life of semaglutide?
The Ozempic injection prescribing information describes an elimination half-life of approximately one week and circulating semaglutide for about five weeks after the last dose. Half-life describes drug concentration decline under specified conditions. It is not a countdown for appetite effects, an individual clearance guarantee or a shelf-life claim for a laboratory sample.
How much weight did people lose with semaglutide?
In STEP 1, adults with obesity or overweight and a weight-related condition, without diabetes, lost an average 14.9% of baseline body weight at 68 weeks with the tested semaglutide regimen versus 2.4% with placebo. Other populations, formulations, treatment conditions and analyses produced different results. These are clinical trial averages, not promises for an individual or claims about research materials.
What happens when you stop semaglutide?
Weight regain occurred on average in withdrawal research. In the STEP 1 extension, a selected subgroup regained about two-thirds of its previous loss during a year after both medication and structured lifestyle support ended. STEP 4 separately found regain after medication withdrawal while lifestyle support continued. Neither study establishes a universal self-directed taper or cycling plan.
What are the side effects of semaglutide?
Nausea, vomiting, diarrhea, constipation and abdominal symptoms are common adverse effects in prescribing information. Serious warnings include pancreatitis, severe gastrointestinal reactions, dehydration-related kidney injury, gallbladder disease, hypersensitivity and aspiration during anesthesia or deep sedation. Labeling also contains a boxed thyroid-tumor warning based on rodent findings, with human relevance unknown. Suitability requires individual clinical assessment.
Is semaglutide FDA approved for weight loss?
Specified Wegovy products have United States weight-management indications. The injection and tablet labels differ in eligible populations and other uses. Approval belongs to those finished products and their labeled indications; it does not extend to every product or research material containing semaglutide.
Is semaglutide a GLP-1 or a dual agonist?
Semaglutide is a GLP-1 receptor agonist. Tirzepatide engages both GIP and GLP-1 receptors. This mechanistic distinction helps organize the evidence, but receptor count alone does not establish which medicine is preferable for a particular outcome or person.
Does a semaglutide COA prove pharmaceutical equivalence?
No. A certificate of analysis reports the tests and sample identified in that document. Chromatographic area purity and identity testing do not independently establish calibrated active content, formulation equivalence, sterility, endotoxin control, stability or clinical safety. Apex research materials are not intended for human or veterinary use.
Semaglutide primary references and scientific background
Original experiments and trials are distinguished from physiology and development reviews. Current product labels are linked alongside the relevant statements above.
- Holst et al. (2007). The physiology of glucagon-like peptide 1. PMID 17928588.
- Lau et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. PMID 26308095.
- Marso et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. PMID 27633186.
- Sorli et al. (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. PMID 28110911.
- Drucker et al. (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. PMID 29617641.
- Knudsen et al. (2019). The Discovery and Development of Liraglutide and Semaglutide. PMID 31031702.
- Husain et al. (2019). Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. PMID 31185157.
- Aroda et al. (2019). PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. PMID 31186300.
- Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. PMID 33567185.
- Wadden et al. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. PMID 33625476.
- Davies et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. PMID 33667417.
- Rubino et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. PMID 33755728.
- Lincoff et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. PMID 37952131.
- Buckley et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. PMID 30429357.
- Wilding et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. PMID 35441470.
- Perkovic et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. PMID 38785209.
- McGuire et al. (2025). Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. PMID 40162642.
- Sanyal et al. (2025). Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. PMID 40305708.
- Wharton et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. PMID 40934115.
- Wharton et al. (2025). Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. PMID 40961952.
- Tronieri et al. (2026). Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. PMID 42323166.
- Plotkin et al. (2026). Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes. PMID 42225300.
Authorship and editorial review
Written by Nicholas Tremelling. Reviewed by the Apex Laboratory Editorial Team under the Apex editorial standards. This educational guide keeps clinical evidence, formulation-specific labeling and laboratory documentation distinct. It does not provide a treatment, dose or cycling protocol.
